MARKET NEWS


Hovione & iBET Announce Strategic Collaboration
PDS Biotechnology Establishes Partnership With Head & Neck Cancer Alliance
Santhera & ReveraGen Announce Positive & Statistically Highly Significant Topline Results
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
uniQure Announces Positive Recommendation to Advance Phase 1/2 Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
Ocugen On Track to Submit EUA Application to US FDA for its COVID-19 Vaccine Candidate

  FEATURED EDITORIAL


  COMPANY PROFILE


DRUG DELIVERY EXPERTS (DDE LABS) is your go-to partner for Contract Drug Product R&D, Simple Solution to Complex Liquid Formulations, and Clinical Trial Materials Manufacturing in a Sterile Suite. We specialize in parenteral drug products from solutions to particulate systems and long-acting technologies. We are also experienced in oral, nasal, and ocular formulation development. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Mirati Therapeutics & Zai Lab Enter Development & Commercialization Collaboration

Mirati Therapeutics & Zai Lab Enter Development & Commercialization Collaboration

Mirati Therapeutics, Inc. and Zai Lab Limited recently announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule….

Immutep Enters Into New Collaboration With Merck KGaA

Immutep Enters Into New Collaboration With Merck KGaA

Immutep Limited recently announced a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany, for a Phase 1/2a clinical trial in patients with….

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline Into Cancer & Fibrotic Diseases

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline Into Cancer & Fibrotic Diseases

Corbus Pharmaceuticals Holdings, Inc. recently announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of….

Aptamer Group Collaborates With World-Leading Pharmaceutical Company to Evaluate Optimer Technology

Aptamer Group Collaborates With World-Leading Pharmaceutical Company to Evaluate Optimer Technology

Aptamer Group recently announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda Pharmaceutical Company Limited…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 16 – Parenteral Contract Manufacturing
June 23 – Controlled Release